MorphoSys AG (ETR:MOR)‘s stock had its “buy” rating reissued by investment analysts at J P Morgan Chase & Co in a research note issued on Thursday.

MOR has been the topic of several other reports. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) price objective on shares of MorphoSys AG and gave the company a “neutral” rating in a report on Thursday, September 7th. Commerzbank Ag set a €76.00 ($89.41) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a report on Thursday, August 31st. Deutsche Bank AG set a €90.00 ($105.88) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a report on Thursday, September 7th. Berenberg Bank set a €68.00 ($80.00) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a report on Friday, July 14th. Finally, Independent Research GmbH set a €77.00 ($90.59) price objective on shares of MorphoSys AG and gave the company a “buy” rating in a report on Thursday, September 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. MorphoSys AG presently has a consensus rating of “Buy” and an average target price of €79.00 ($92.94).

TRADEMARK VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2017/11/02/morphosys-ag-mor-earns-buy-rating-from-j-p-morgan-chase-co.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.